Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report.

Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF.

Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients.

This is an extended open study of oral prophylactic treatment with egg yolk antibodies against Pseudomonas aeruginosa, Anti-Pseudomonas IgY, of 17 Swedish patients with cystic fibrosis. They have been on prophylactic IgY treatment for up to 12 years and altogether for 114 patient years. A group of 23 Danish CF patients served as control.

More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report.

Immunotherapy with specific antibodies is an alternative to antibiotics for the prevention of infections in humans and animals. We have used orally administered immunoglobulin Y (IgY) preparations, purified from eggs of hens immunized with Pseudomonas aeruginosa bacteria, to prevent pulmonary P. aeruginosa infections in a group of patients with cystic fibrosis (CF).

Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study.

Respiratory infection is the major cause of morbidity and mortality in cystic fibrosis (CF) patients. Chronic Pseudomonas aeruginosa (PA) infections ultimately occur in virtually all patients. It is impossible to eradicate PA when a patient has been chronically colonized.

Retention of specific yolk IgY in the human oral cavity.

Introduction: The increasing prevalence of antibiotic-resistant bacteria emphasises the need for new treatments that can replace traditional antibiotics. Oral immunotherapy with yolk antibodies from hyperimmunised hens is a new promising treatment strategy, primarily for infections in the mouth and gastrointestinal tract. Several studies show that bacterial and viral infections can be prevented with egg yolk immunoglobulin (IgY) in a dose-dependent manner.

Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.

Oral administration of specific antibodies is an attractive approach to establish protective immunity against gastrointestinal pathogens in humans and animals. The increasing number of antibiotic-resistant bacteria emphasize the need to find alternatives to antibiotics. Immunotherapy can also be used against pathogens that are difficult to treat with traditional antibiotics.

Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden.

Children with cystic fibrosis (CF) diagnosed by neonatal screening have a better nutritional development and other advantages compared with those in a nonscreened group. The two-tier immunoreactive trypsinogen (IRT)/DNA screening protocol has been found superior to the single-tier IRT approach, improving the positive predictive value and thus reducing the false-positive rate. However, variations of the DNA test are required for different populations.

[Further clarification of functional issues in cystic fibrosis. Current research and future prospects].

First rate collaboration between clinicians and research scientists in a multiplicity of fields have brought new hope to patients with cystic fibrosis (CF). The gene, mutations of which give rise to the disease, has been exhaustively mapped, and the functional defects are becoming steadily clearer. Diagnosis is continually being improved and simplified.

[Cystic fibrosis--an ancient disease with renewed topicality. History and clinical practice].

Cystic fibrosis (CF) is a general exocrinopathy chiefly characterised by airway and nutritional symptoms, though several other organ systems may also be affected. Intensive collaboration between clinicians and research scientists has enabled great advances to be made in our understanding and treatment of the disease. New mucolytic treatment, new approaches to combating infections, and improvements in nutrition have already appeared.

Increased serum concentrations of carbohydrate-deficient transferrin (CDT) in patients with cystic fibrosis.

Carbohydrate-deficient transferrin (CDT) has been reported to be one of the best laboratory markers in serum (S) for detection of alcohol abuse. We have studied S-CDT values in cystic fibrosis (CF) patients and show that CF patients have increased S-CDT values without high alcohol consumption. CF patients have abnormalities in their protein glycosylation and sialylation, which may explain the increased S-CDT values.

Exhaled nitric oxide in paediatric asthma and cystic fibrosis.

Nitric oxide (NO) is present in exhaled air of humans. This NO is mostly produced in the upper airways, whereas basal NO excretion in the lower airways is low. Children with Kartagener's syndrome have an almost total lack of NO in nasally derived air, whereas adult asthmatics have increased NO in orally exhaled air.

Ribonuclease and its inhibitor in red blood cells in CF.

A disturbed activity of ribonuclease (RNAase) and its natural inhibitor was found in cystic fibrosis patients (CF); Heterozygotes had normal RNAase but increased inhibitor activities; both groups compared with age-matched controls. RNAase is involved in the breakdown of RNA. In the cell it is bound to an inhibitor and thus inactive (Bardoń 1976).

Increased glycolytic activity in red blood cells of CF patients.

An increased activity of the glycolytic pathway was found in RBC: s from CF patients, compared to age-matched controls. Heterozygotes showed a tendency to increased activity.

Increasing survival of Swedish patients with CF.

A decade ago the majority of cystic fibrosis (CF) patients in Sweden died in childhood or adolescence. However, better knowledge of the underlying defect and understanding of how to treat the symptoms have resulted in an ever increasing survival rate. The results support the idea that: 1.

Dopamine and catecholamines in cystic fibrosis in response to a marathon race.

The excretions of 3,4-dihydroxyphenylalanine (DOPA) metabolites and 5-hydroxyindoleacetic acid (5-HIAA) were followed before, during, and after a marathon race in three patients with cystic fibrosis (CF) and three healthy controls. Moderately increased DOPA excretions in CFs compared with controls before, during, and after the race support the idea that there is an altered metabolism of DOPA in CF. Noradrenaline, adrenaline, homovanillic acid, and vanilmandelic acid were increased in CFs compared with controls mainly during and after the race, which might be a reflection of the heavier working intensity that the CF patients had in comparison with their healthy controls.

Fatty acids in cystic fibrosis in response to a marathon race.

Lipid metabolism was studied in three cystic fibrosis (CF) patients (18 years old) and three healthy controls (35-40 years old) who completed the New York Marathon 1984. Lipase was not detectable in plasma from two of the CF patients, but in one CF patient with a functioning pancreas and in the three controls it increased during and after the run. Cholesterol concentrations were lower in all patients than in the controls.

Biochemical changes and endocrine responses in cystic fibrosis in relation to a marathon race.

Biochemical changes and endocrine responses during the New York Marathon (42195 m) were investigated in three 18-year-old male adolescents with cystic fibrosis (CF) and three healthy men who accompanied the CFs during the race. The ambient temperature was 20 degrees-28 degrees C and the relative humidity 98%-75% during the run. The CF patients, who had Shwachman scores of 60, 85 and 95 completed the run without major problems in 6.

Biochemical changes and endocrine responses in cystic fibrosis in relation to incremental maximal exhaustive exercise.

The purpose of this study was to compare biochemical changes and endocrine responses during an incremental maximal bicycle test in three well-trained 18-year-old patients with cystic fibrosis (CF) and in three healthy controls. Although the blood concentration at rest of the white cell count, haptoglobin, phosphorus, urea, creatinine, and uric acid were somewhat different in the two groups, the CF patients had similar biochemical changes in response to the exercise compared with the healthy men. The endocrine responses to exercise seemed to be different between the two groups with regard to changes in cortisol, growth hormone, and testosterone concentrations.